Kymab

Kymab. It was a biotechnology company founded in 2009 by Allan Bradley, a pioneer in genetic engineering from the Wellcome Sanger Institute. Headquartered in the Cambridge Science Park, the firm specialized in leveraging a proprietary transgenic mouse platform to discover and develop fully human monoclonal antibody therapeutics. The company gained significant attention within the pharmaceutical industry for its innovative approach before being acquired by the French multinational Sanofi in 2021.

History

Kymab was established in 2009 following pioneering work in recombinant DNA technology at the Wellcome Sanger Institute, with seed funding from the venture capital firm The Wellcome Trust. The company's early research was conducted in collaboration with the Babraham Institute, focusing on building its foundational intellectual property. In 2014, Kymab secured a substantial Series B financing round co-led by Bill & Melinda Gates Foundation and The Woodford Patient Capital Trust, which provided capital to expand its therapeutic programs. This period saw the company grow its operations at the Cambridge Science Park, attracting talent from global institutions like Genentech and MedImmune. By 2017, under the leadership of CEO Simon Sturge, formerly of Kymab, the company had advanced multiple candidates toward clinical trials, positioning itself as a key player in the European biotechnology landscape.

Technology and Platform

The core of Kymab's operations was its proprietary Kymouse platform, a suite of transgenic mouse strains engineered using CRISPR and homologous recombination techniques to contain large, diverse segments of the human immunoglobulin gene repertoire. This technology, developed from research at the Wellcome Sanger Institute, allowed for the natural generation of a broad spectrum of fully human monoclonal antibodies in response to immunization with target antigens. The platform's design overcame limitations of earlier systems like the HuMAb-Mouse from Medarex and Regeneron's VelocImmune technology by offering greater antibody diversity and V(D)J recombination fidelity. This enabled the efficient discovery of high-affinity therapeutic candidates against complex targets, including GPCRs and ion channels, which are often challenging for conventional antibody discovery methods.

Key Programs and Collaborations

Kymab advanced a pipeline of antibody therapies targeting immunology and oncology. Its lead candidate, KY1005, a monoclonal antibody targeting OX40L, entered Phase II clinical trials for treating atopic dermatitis and graft-versus-host disease. In oncology, the company developed KY1044, an ICOS agonist antibody evaluated in combination with atezolizumab for solid tumors. A significant early collaboration was with the Bill & Melinda Gates Foundation, focusing on discovering antibodies for global health targets like malaria and HIV. The company also established a multi-target partnership with Novo Nordisk to discover therapies for autoimmune diseases and entered into a research agreement with Mereo BioPharma. These strategic alliances validated the Kymouse platform's utility and provided non-dilutive funding to advance internal programs toward clinical development.

Intellectual Property and Litigation

Kymab was involved in a high-profile patent infringement lawsuit against Regeneron Pharmaceuticals concerning its VelocImmune mouse technology. The legal battle, heard in the High Court of Justice in London, centered on a foundational patent held by Kymab and the Medical Research Council related to transgenic mouse engineering. In 2016, the court initially ruled in favor of Regeneron, but this decision was overturned in 2020 by the Supreme Court of the United Kingdom, which upheld the validity of Kymab's key intellectual property. This landmark ruling reinforced the company's freedom to operate and significantly enhanced its valuation, demonstrating the strategic importance of its patent estate in the competitive field of antibody therapeutics.

Acquisition by Sanofi

In January 2021, the French pharmaceutical giant Sanofi announced its acquisition of Kymab for an upfront payment of approximately $1.1 billion, with potential contingent value rights adding up to $350 million more. This strategic move, led by Sanofi's then-CEO Paul Hudson, was aimed at bolstering Sanofi's immunology pipeline, particularly by gaining full control of the promising OX40L program, KY1005. The integration of Kymab's Kymouse platform into Sanofi's R&D operations in Vitry-sur-Seine and Frankfurt provided the larger company with a powerful new engine for biologic drug discovery. The acquisition was seen as a major validation of the United Kingdom's biotechnology sector and one of the largest European biotech exits of the year, following other significant deals like AstraZeneca's purchase of Alexion Pharmaceuticals.